TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04018144

Intervention type: DIAGNOSTIC_TEST
Intervention: Gingiva Biopsy Sampling
Description: Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gingiva Biopsy Sampling
Description: Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gingiva Biopsy Sampling
Description: Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
Study: NCT01033344

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection 1x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Intradermal injection 1x8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
Study: NCT00947856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
Study: NCT03824379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidiabetic
Description: insulin or oral hypoglycemics
Study: NCT01514448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus was used as commercially available formulated tablets of 10 mg strength
Study: NCT03997240

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chiropractic Applied Clinical Neuroscience
Description: Chiropractic Applied Clinical Neuroscience makes use of chiropractic care in addition to application of therapies designed to stimulate multisensory reintegration and cerebellar coordination. The multisensory reintegration and cerebellar therapies make use of the body's own sensory receptors as a target, with the purpose of realigning the brain's interpretation of different afferent signals. Observation of motor and autonomic output patterns during and after sensory stimulation afford the clinician real-time feedback, providing for adaptation of the sensory based protocol.
Study: NCT04614181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle Resource drink
Description: Beverage (Nestle RESOURCE). Each serving is 237ml containing 53.6g of carbohydrate and 9g of protein. Intervention group will consume two servings of the carbohydrate beverage (53.6g each, total of approximately 100g) on the day before surgery and one serving up to 6 hours prior to scheduled surgery time.
Study: NCT04962555

Intervention type: PROCEDURE
Intervention: Meniscus Suture
Description: Patients with knee joint meniscus injury undergoing meniscus suture

Intervention type: PROCEDURE
Intervention: Partial meniscus resection
Description: Patients with knee joint meniscus injury undergoing partial meniscus resection

Intervention type: PROCEDURE
Intervention: Subtotal meniscus resection
Description: Patients with knee joint meniscus injury undergoing subtotal meniscus resection

Intervention type: PROCEDURE
Intervention: Complete meniscectomy
Description: Patients with knee joint meniscus injury undergoing complete meniscectomy
Study: NCT01497938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature
Description: Automatic suspension of insulin delivery when glucose is low.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
Description: No Automatic suspension of insulin delivery when glucose is low.
Study: NCT03580343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: tofacitinib extended release, 11mg, daily, oral
Study: NCT01432132

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Face-to-face audio recorded interview. It should take about 1 hour to complete.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Face-to-face audio recorded interview. It should take about 1 hour to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about demographic information such as age and ethnicity.
Study: NCT00671879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisoprodol SR 700 mg
Description: 700 mg twice daily tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisoprodol SR 500 mg
Description: carisoprodol SR 500 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet
Study: NCT01483872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC/Tigecycline/Heparin combination lock solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard anticoagulant (Heparin or Citrate)
Study: NCT01405976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: life style modification, noninvasive ventilation, CPAP
Description: life style modification, noninvasive ventilation, CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: life style modification, noninvasive ventilation, CPAP
Description: life style modification, noninvasive ventilation, CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: life style modification, noninvasive ventilation, CPAP
Description: life style modification, noninvasive ventilation, CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: life style modification, noninvasive ventilation, CPAP
Description: life style modification, noninvasive ventilation, CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: life style modification, noninvasive ventilation, CPAP
Description: life style modification, noninvasive ventilation, CPAP
Study: NCT03958279

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurement of residual volume in the urinary bladder
Description: Aim of this study is to asses post voiding residual volume by ultrasound scan 3th day after delivery with consecutive scan after 6 weeks, and determination of data dispersion among the population of primiparas.

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire
Description: Simple questionaire concerning voiding problems, infectious complications, medicaments and breastfeeding during puerperium period (6weeks)
Study: NCT00614055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target dose titration scheme, injection s.c., once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 1500-2000 mg/day
Study: NCT04614181

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual fracture care as determined by clinical team
Study: NCT02159157

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise prescription
Description: A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
Study: NCT02131285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory training
Study: NCT05930626

Intervention type: OTHER
Intervention: Biomarkers of acrylamide, glycidol, POPs, PFAS
Description: These are food contaminants (acrylamide, glycidol) and environmental pollutants (POPs, PFAS). Assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with POPs and PFAS using a prospective cohort study utilizing and integrating various 'OMICs' technologies.

Intervention type: OTHER
Intervention: Biomarkers of acrylamide, glycidol, POPs, PFAS
Description: These are food contaminants (acrylamide, glycidol) and environmental pollutants (POPs, PFAS). Assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with POPs and PFAS using a prospective cohort study utilizing and integrating various 'OMICs' technologies.
Study: NCT00614055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1500-2000 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1500-2000 mg/day
Study: NCT02878850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Blood Pressure
Description: Subjects will have their blood pressure kept in a higher range.
Study: NCT01991509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBR-101 IV
Description: LBR-101 Administered Intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBR-101 IV
Description: LBR-101 Administered Intravenously
Study: NCT03854084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The cranial osteopathic techniques
Description: Technique of the temporal bones in favor of the free movement. Ear Pull technique: the hands of the osteopath holds the auricle of the individual with the thumb, index and the middle finger in a tweezer shape and with the elbows resting over the stretcher. Ruddy technique: The osteopath puts the thumbs on the eyelid of each eyeball.
Study: NCT01991509

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LBR-101 IV
Description: LBR-101 Administered Intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBR-101 SC
Description: LBR-101 Administered Subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBR-101 SC
Description: LBR-101 Administered Subcutaneously
Study: NCT03854084

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Simulation of the techniques was used in the interventional group
Study: NCT03588156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benapenem
Description: Dose-escalation For 11 level dose groups A1 \~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
Study: NCT01991509

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LBR-101 SC
Description: LBR-101 Administered Subcutaneously
Study: NCT03588156

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01992289

Intervention type: DRUG
Intervention: EDI200
Description: Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
Study: NCT01506089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 36 degrees Celsius
Description: Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
Study: NCT05488184

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavoured Oral Nutritional Supplement (ONS)
Description: Sensory analysis of different ONS of sweet (pineapple, tropical, brownie) and acid flavoured (tomato, ham)
Study: NCT01199406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: 0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: 0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
Study: NCT02708290

Intervention type: OTHER
Intervention: MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time
Description: Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.~MITA verbal activities start with simple vocabulary-building exercises and progress toward exercises aimed at higher forms of language, such as noun-adjective combinations, spatial prepositions, recursion, and syntax. All exercises are deliberately limited to as few nouns as possible since the aim is not to expand a child's one-word vocabulary, but rather to teach him/her to integrate mental objects in novel ways by utilizing prefrontal synthesis (PFS). MITA activities outside of the verbal domain aim to provide the same PFS training visually through implicit instructions.

Intervention type: OTHER
Intervention: MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time
Description: Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.~MITA verbal activities start with simple vocabulary-building exercises and progress toward exercises aimed at higher forms of language, such as noun-adjective combinations, spatial prepositions, recursion, and syntax. All exercises are deliberately limited to as few nouns as possible since the aim is not to expand a child's one-word vocabulary, but rather to teach him/her to integrate mental objects in novel ways by utilizing prefrontal synthesis (PFS). MITA activities outside of the verbal domain aim to provide the same PFS training visually through implicit instructions.
Study: NCT04511520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training program

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Study: NCT04637711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision
Description: Only visible lesions and necrotic tissues, such as abscess cavity, sinus tract and fistula, were removed intraoperatively, while normal glands and fat were retained. Preoperative ultrasound was used to locate the lesion area and then the surgical incision was designed. Intraoperative ultrasound examination of latent small lesions, resection of lesions visible under ultrasound, and then a full breast exploration, one finger page incision interval.Radially cut from the base to the subcutaneous, lesions were found and treated locally. After removal of lesion, fully using the syringe, in turn, use of 3% hydrogen peroxide solution, 1% eniodine, saline water is widely jet pulse washing, and around the lesions base. After rinsing, soak in 1% active iodine for 10min, then rinse with normal saline until the liquid is clear. Breast tumor Surgery (Oncoplastic Breast Surgery, OBS) core technology (volume replacement and volume replacement).
Study: NCT00405431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: 1 drop in study eye twice a day X 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endura (artificial tears)
Description: 1 drop in study eye twice a day X 6 months
Study: NCT03821259

Intervention type: OTHER
Intervention: Psychological measures
Description: Participants will be asked to provide basic demographic information and to complete five measures, screening for cognitive impermanent and measuring PTSD symptoms, lifetime trauma exposure, emotion regulation and group identification.
Study: NCT00596687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Insulin glargine once daily SQ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: scheduled glulisine given SQ at mealtime TID; none given if patient NPO
Study: NCT01365078

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echium oil (SDA-rich oil)
Description: The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: high-oleic acid sunflower oil (HOSO) (low in SDA)
Description: The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
Study: NCT01999699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV
Study: NCT00627965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: 50mg tds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tds
Study: NCT03030560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
Study: NCT00887848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lokomat training
Description: 15 sessions of Lokomat training within 5 weeks (3 trainings/week)

Intervention type: OTHER
Group type: OTHER
Intervention: Lokomat training
Description: 15 sessions of Lokomat training within 5 weeks (3 trainings/week)
Study: NCT05832853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wu Qin Xi exercise
Description: The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wu Qin Xi, resistance training and endurance training
Description: During the first 8 weeks, the training consists of learning and consolidating the movements of the Wu Qin Xi. In the second 16 weeks, participants perform a full set of movement exercises. Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and two sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 15 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training and endurance training
Description: Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and three sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 30 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
Study: NCT01497912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80mg once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily for 8 weeks
Study: NCT03014544

Intervention type: DEVICE
Intervention: Computer- administered test battery
Description: Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.

Intervention type: DEVICE
Intervention: Computer- administered test battery
Description: Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.

Intervention type: DEVICE
Intervention: Examiner- administered test battery
Description: Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.

Intervention type: DEVICE
Intervention: Examiner- administered test battery
Description: Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.